The Larry J. Shapiro Director, Institute for Public Health, William G. Powderly, MD, associate dean for Clinical and Translational Sciences; co-director of the Washington University Division of Infectious Diseases and director of the Institute for Clinical and Translational Sciences, is principal investigator on a new study of anti-inflammatory drugs in COVID-19 patients. According to a university news release, the clinical trial is funded by the National Institutes of Health, and “aims to enroll 2,000 patients hospitalized with moderate to severe COVID-19, and is expected to last six months.”
Read the story in the Post-Dispatch, watch the story on KMOV-TV and hear a related story on St. Louis Public Radio with other WashU physicians involved in the study.